US Considers Allowing Most China Pharma Deals
The US Treasury Department is drafting rules for pharmaceutical investments in China that would likely permit most drug licensing deals. The proposed framework aims to balance national security with industry access to fast-growing treatments.
Xurve View
Insights:
Xurve View
The United States is drafting rules that would preserve pharmaceutical licensing deals with China, protecting billions of dollars in cross-border investments. This approach marks a departure from tighter restrictions placed on other industries under national security legislation. The proposed framework ensures major drugmakers can continue tapping overseas pipelines despite pressure from lawmakers.
